Sitagliptin and Endothelial Dysfunction

• Status: Unknown status
• Trial end date: 2015-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Over the years, numbers of cardioprotective drugs have been evaluated to attenuate lethal ischemia-reperfusion (IR) injuries. There is little study whether sitagliptin protects against endothelial dysfunction induced by IR injury in humans.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Kyunghee University Medical Center
• Treatments: Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• healthy volunteer age 20 to 40 years

• non-smoker

Exclusion Criteria:

• High blood pressure (>140/90 mmHg) or any antihypertensive medications

• diabetes

• any cardiovascular disease

• kidney disease

• thyroid disease

• cerebrovascular disease

• liver disease (bilirubin level >2 mg/dl)

• pregnancy

• body mass index >25 kg/m2